“I look forward to participating in an event that brings together the most innovative companies and ideas in the industry. We are excited to be a part of the revolution that is happening in healthcare.” - Dr. Jessica Richman, PhD, co-founder and CEO of uBiome
SAN FRANCISCO (PRWEB) May 07, 2018
uBiome, the leader in microbial genomics, announced today that co-founder and CEO, Dr. Jessica Richman, PhD, will present at the first annual HLTH Conference — an event designed to advance healthcare innovation and promote dialogue within the industry. HLTH will be held at The Aria in Las Vegas, May 6-9, 2018.
Dr. Richman will participate in a panel discussion titled, “Consumers’ Front Door to their DNA at Home and Work,” which will feature a discussion of how genomic and other types of testing can help consumers.
About attending HLTH, Dr. Jessica Richman, PhD, said: “I look forward to participating in an event that brings together the most innovative companies and ideas in the industry. We are excited to be a part of the revolution that is happening in healthcare.”
uBiome’s technology platform is based on the largest dataset of human microbiomes in the world (over 250,000 samples), covered by six issued patents (and over 100 pending applications), and used in over 20 peer-reviewed publications and presentations. This platform has been used by over 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, University of California, San Francisco, University College London, and University of Sydney.
The company’s Scientific Advisory Board includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), and other leading scientists. Their Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Tryzon (Cedars-Sinai Medical Center), Dr. Robynne Chutkan (Georgetown University Hospital), and Michael Docktor (Boston Children’s Hospital).
The session will be moderated by Noah Knauf, General Partner at Kleiner Perkins, on Tuesday, May 8th at 4:10 p.m. Dr. Richman will be joined by Dr. Jill Hagenkord, Chief Medical Officer of Color and Clayton Lewis, Co-Founder and CEO of Arivale.
HLTH is the leading event for innovation in healthcare. It’s an unprecedented, large-scale forum for individuals, companies, and policymakers who are reshaping the healthcare industry to learn, collaborate and evolve. The event is unique in bringing together all key stakeholders, ranging from established payers, providers, employers and pharma services to disruptive startups and prolific investors, as well as representatives from government, media and analysts. By leading the development of a new industry dialogue and ecosystem, HLTH's mission is to drive substantial reductions in healthcare costs and dramatic increases in healthcare quality. HLTH takes place on May 6-9, 2018.
Founded in 2012, uBiome is the world’s leading microbial genomics company with a mission to transform the science of the microbiome into reliable, accurate products and services that improve people’s lives. uBiome is funded by Y Combinator, Andreessen Horowitz, and 8VC, as well as other leading investors. The company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018.